A pioneering personalized liquid biopsy assay, MRD4U, has been developed to track pediatric central nervous system tumors with exceptional sensitivity. This genomic assay enables early detection and dynamic monitoring of CNS tumors in children, potentially improving clinical outcomes by allowing timely therapeutic interventions. The work represents a significant advancement in pediatric oncology diagnostics.